A novel therapeutic drug (copper nicotinic acid complex) for non-alcoholic fatty liver

Liver International

Volumn 27, Issue 4, 2007, Pages 454-464

  Salama, Ragaa H M ^a   Nassar, Ahmed Y A ^a   Nafady, Allam A M ^b   Mohamed, Hesham H T ^c  

^a Assiut University Faculty of Medicine   (Egypt)

^b Assiut University   (Egypt)

^c Al Azhar University   (Egypt)

Author keywords

Animal model; Copper complex; Fatty liver; Nutrition

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; COPPER COMPLEX; GLUTATHIONE; LIPID PEROXIDE; NICOTINIC ACID; NITRIC OXIDE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; CELL DEGENERATION; CELL FUNCTION; CELL STRUCTURE; CONTROLLED STUDY; HISTOPATHOLOGY; LIPID BLOOD LEVEL; LIVER LEVEL; LIVER WEIGHT; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; RAT; TISSUE SECTION; WEIGHT GAIN;

ANIMALS; BODY WEIGHT; COPPER; DRUG EVALUATION, PRECLINICAL; ENZYME TESTS; FATTY LIVER; LIPIDS; LIVER; NIACIN; OXIDATIVE STRESS; RATS; TREATMENT OUTCOME;

EID: 34047211289     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01460.x     Document Type: Article

References (35)

1. Dam-Larsen S, Franzmann MB, Christoffersen P, et al. Histological characteristics and prognosis in patients with fatty liver. Scand J Gastroenterol 2005; 40: 460-7.
2. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
3. Mendez-Sanchez N, Chavez-Tapia NC, Uribe M. An update on non-alcoholic fatty liver disease. Rev Invest Clin 2004; 56: 72-8.
4. Andy YuS, Emmet B, Keeffe MD. Non alcoholic fatty liver disease. Rev. Gastroenterol. Disorders 2002; 2: 11-9.
5. Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Met 2002; 16: 703-16.
6. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: An evolving diagnosis. Can J Gastroenterol 2000; 14: 321-6.
7. Mcgahan MC. Copper and aspirin treatment increase the antioxidant activity of plasma. Agents Actions 1990; 31: 59-64.
8. El-Saadani MA, Nassar AY, AbouEl-Ela SH, et al. The protective effect of copper complexes against gastric mucosal ulcer in rats. Biochem Pharmacol 1993; 46: 1011-8.
9. El-Saadani MA. A combination therapy with copper nicotinate complex reduces the adverse effects of 5-fluorouracil on patients with hepatocellular carcinoma. J Exp Ther Oncol 2004; 4: 19-24.
10. Davidson MH. Management of dyslipidemia in patients with complicated metabolic syndrome. Am J Cardiol 2005; 2296 (4A): 22E-5E.
11. Mookerjee A, Mookerjee Basu J, Dutta P, et al. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis. Clin Cancer Res 2006; 15: 4339-49.
12. Gohar MA, Dratoviscky M. Synthesis and infrared examination of Cu (I) halide complexes with nicotinic acid and its ethyl ester. Coll Czech Chem Commun 1975; 40: 26-32.
13. Delzenne NM, Hernaux NA, Taper HS. A new model of acute liver steatosis induced in rats by fasting followed by re-feeding high carbohydrate-fat free diet. Biochemical and morphological analysis. Hepatology 1997; 26: 880-5.
14. Grattagaliano I, Gianluigi V, Caraceni P, et al. Starvation impairs antioxidant defense in fatty livers of rats fed a choline-deficient diet. Nutrition 2000; 130: 2131-6.
15. Grattagaliano I, Gianluigi V, Caraceni P, et al. Experimental observation and clinical implications of fasting and diet supplementation in fatty livers. Eur Rev Med Phrmacol Sci 2003; 7 (1): 1-7.
16. Van Bezooijen RL, Que I, Ederveen AG, et al. Plasma nitrate+nitrite level are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats. J Endocrinol 1998; 159: 27-34.
17. Satoh K. Serum lipid peroxide in cerbrovascular disorders determined by a new calorimetric method. Clin Chem Acta 1978; 90: 37-43.
18. Misra H, Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 215 (10): 3170.
19. Houchin J. Methods of determination of serum ceruloplasmin level. Am J Biochem 1958; 13: 41.
20. Beulter E, Duran O, Kelly BM. Improved method for the determination of glutathione in tissue homogenate. J Lab Clin Med 1963; 61: 882-8.
21. Zollner N, Kirsch K. Colorimetric method for the in vitro determination of serum and tissue total lipid. Z Ges Exp Med 1962; 135: 545.
22. Portincasa P, Grattagaliano I, Palmieri VO, Palasciano G. The emerging problem of nonalcoholic steatohepatitis (NASH). Rom J Gastroentrol 2005; 14: 43-51.
23. Bahcecioglu IH, Yalniz M, Ilhan N, et al. Levels of serum vitamin A, alpha-tocopherol and malondialdehyde in patients with non-alcoholic steatohepatitis: Relationship with histopathologic severity. Int J Clin Pract 2005; 59 (3): 318-23.
24. Day CP, James OF. Steatohepatitis: A tale of two "hits". Gastroenterology 1998; 14: 842-5.
25. Yang SQ, Zhu H, Li Y, et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biockem Biophys 2000; 378: 259-68.
26. Letteron P, Fromenty B, Terris B, et al. Acute and chronic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24: 200-8.
27. Sreekumar R, Wiesner RH, Nagomey DM. Unique hepatic expression in NASH-candidates for a genetic bases of disease. Gastroenterology 2000; 120: A-119(580).
28. Klotz LO, Kroncke KD, Buchczyk DP, Sies H. Role of copper, zinc, selenium and tellurium in the cellular defense against oxidative and nitrosative stress. J Nutr 2003; 133 (5): 1448S-51S.
29. Lewis AJ. The role of copper in inflammatory disorders. Agents Actions 1984; 15 (5-6): 513-9.
30. Trinchero A, Bonora S, Tini A, Fini G. Spectroscopic behavior of copper complexes of non-steroidal anti-inflammatory drugs. Biopolymers 2004; 574 (1-2): 120-4.
31. Blincoe C, Chidambaram M, Salai H, et al. Pharmacokineticdistributionof 67Cu(II)2[3,5-diisopropyl (carboxy-14C) salicylate] 4 among murine tissues. Curr Med Chem 2004; 11 (22): 3007-15.
32. Huber W, Menander-Huber KB. Orgotein. Clinics in Rheumatic Diseases: Anti-Rheumatic Drugs, 1980; 6: 465-498.
33. Baquial JGL, Sorenson JRJ. Down-regulation of NADPH-diaphorase (nitric oxide synthase) may account for the pharmacological activities of Cu (II) 2 (3,5-diisopropy1salicyIate). J Inorg Biochem 1995; 60: 133-48.
34. Fujimori T, Yamada S, Yasui H, Sakurai H, In Y, Ishida T. Orally active antioxidative copper (II) aspirinate: Synthesis, structure, characterization superoxide scavenging activity, and in vitro and in vivo antioxidative evaluations. J Biol Inorg Chem 2005; 28: 1-11.
35. Megalla SE, Nassar AY, Gohar MAS. The role of copper (I)- nicotinic acid complex on Kojik acid biosynthesis by Aspergillus flavus. J Basic Microbiol 1987; 27 (1): 29-33.